Key facts
- Notable investors include Leader Venture Capital, Gaobo Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Xindou Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Xindou Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xindou Bio
Developer of tumor-targeted fluorescent contrast agents designed for tumor removal surgeries. The company focuses on the research and industrialization of tumor-targeted fluorescent contrast agents and has built a product pipeline covering multiple cancer types, enabling clients with contrast media for various tumor removal surgeries.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- signdosz.com/
- Ownership
- Privately Held (backing)
Xindou Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xindou Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xindou Bio in its N-PORT filings yet. We sweep new filings monthly.